# FDA Grants Early Approval for Expanded Use of ImmunityBio Bladder Cancer Treatment

- URL: https://stocks.freetheai.org/news/fda-grants-early-approval-for-expanded-use-of-immunitybio-bladder-cancer-5208d5
- Published: 2026-10-14T17:05:55Z
- Category: company_news; sentiment: bullish; impact: high
- Symbols: [NASDAQ:IBRX](https://stocks.freetheai.org/symbols/NASDAQ-IBRX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

ImmunityBio Inc. (IBRX) gained early regulatory clearance from the U.S. Food and Drug Administration to expand the use of its bladder cancer drug, Anktiva. The decision allows the therapy to be used alongside Bacillus Calmette-Guérin for adults with high-grade papillary-only non-muscle invasive bladder cancer that did not respond to standard treatment. The approval arrived several months prior to the agency's expected decision date in January.

The expanded clearance broadens the potential market for Anktiva, which was initially approved in 2024 to treat Carcinoma in Situ. Regulators based the decision on shared clinical characteristics between the two forms of cancer, along with trial results showing that 62% of participants achieved a complete response. Shares of ImmunityBio Inc. rose following the news, continuing a strong multi-fold rally this year.

Looking ahead, ImmunityBio Inc. plans to present an update on its bladder cancer clinical progress during an upcoming symposium. The company is also seeking further label expansions into additional stages of bladder cancer as well as treatments for lung cancer, glioblastoma, lymphoma, and lymphopenia.

## Key points

- The U.S. FDA approved ImmunityBio's Anktiva for high-grade papillary-only non-muscle invasive bladder cancer months ahead of its January deadline.
- Anktiva will be delivered directly into the bladder alongside Bacillus Calmette-Guérin for patients who did not respond to prior therapy.
- Approval was supported by clinical trial data where 62% of enrolled patients achieved a complete response.
- ImmunityBio plans to submit further applications to expand Anktiva into additional cancer indications including lung cancer and glioblastoma.

## Questions and answers

### Why did ImmunityBio stock move up?

ImmunityBio stock rose after the U.S. FDA granted early approval for an expanded use of its bladder cancer drug Anktiva. The decision widens the treatable patient population months ahead of the agency's expected January deadline.

### What is the new FDA approval for Anktiva?

The FDA approved Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that has not responded to Bacillus Calmette-Guérin therapy and has not invaded bladder muscle. It is administered with BCG directly into the bladder.

### What clinical trial data supported Anktiva's approval?

The FDA relied on results from the QUILT-3.032 trial, in which 62% of 77 adult participants achieved a complete response. Among responders, 58% maintained the response for at least 12 months and 40% maintained it for at least 24 months.